000 01794cam a2200349 a 4500
003 EG-GiCUC
005 20250223030444.0
008 110905s2011 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aM.Sc
099 _aCai01.11.18.M.Sc.2011.Ah.S
100 0 _aAhmed Farag Ahmed
245 1 0 _aSolube receptor for advanced glycation end products in patients with renal impairment and hemodialysis patients /
_cAhmed Farag Ahmed ; Supervised Hanan Abdelhalim Abdelrahim , Mona Mohamed Roshdy , Layila Rashed
246 1 5 _aالمستقبلات الذاتية لنواتج التسكير النهائية المتقدمة فى مرضى قصور وظائف الكلى ومرضى الغسيل الكلوى
260 _aCairo :
_bAhmed Farag Ahmed ,
_c2011
300 _a114 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
520 _aSolube RAGE is a naturally occurring inhibitor of pathological effects mediated via RAGE . Protective sRAGE levels are decreased in patients with coronary artery disease as well as in patients with hypertension . Patients with decrease renal function arre at high cardiovascular risk and often have hypertension or diabetes factors that decrease renal function
530 _aIssued also as CD
653 4 _aGlycation end products
653 4 _aHemodialysis patients
653 4 _aRenal impairment
700 0 _aHanan Abdelhalim Abdelrahim ,
_eSupervisor
700 0 _aLayila Rashed ,
_eSupervisor
700 0 _aMona Mohamed Roshdy ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSoheir
_eCataloger
942 _2ddc
_cTH
999 _c35047
_d35047